Research Article
PDF EndNote BibTex RIS Cite

Year 2021, Volume 5, Issue 2, 144 - 148, 01.02.2021
https://doi.org/10.28982/josam.831592

Abstract

References

  • 1. Daniel A, Rainer O, Uwe H, Ondrej V, Licia P, Christophe M, et al. Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board. Nephrol Dial Transplant. 2018; Oct 1;33(10):1699-707. doi: 10.1093/ndt/gfx365.
  • 2. Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, et al. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level. Transpl Immunol. 2009; May;21(1):43-9. doi: 10.1016/j.trim.2009.02.002.
  • 3. Loong CC, Lin CY, Lui WY. Expression of interleukin-17 as a predictive parameter in acute renal allograft rejection. Transplant Proc. 2000; Nov;32(7):1773. doi: 10.1016/s0041-1345(00)01382-8.
  • 4. David IP. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005; May 15;10(10):688-91. doi: 10.1016/S1359-6446(05)03395-7.
  • 5. Meng Y, Mouze L, Wei Z, Yingzi M. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513-522. doi: 10.2174/1389200219666180129151948.
  • 6. Byung HC, Kyoung WK, Bo MK, Shang GP, Sun WL, Bum SC, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. PLoS One. 2012;7(7):e42011. doi: 10.1371/journal.pone.0042011.
  • 7. Anne LW, Joseph AB, Ole V. mTOR: more targets of resveratrol?. Expert Rev Mol Med. 2013; Sep 23;15:e10. doi: 10.1017/erm.2013.11.
  • 8. Tomasz S, Katarzyna S. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015; Jun;1852(6):1145-54. doi: 10.1016/j.bbadis.2014.10.013.
  • 9. Lynn DC, R Neal S, Robert BC. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol. 2008;3:189-220. doi: 10.1146/annurev. pathmechdis.3.121806.151508.
  • 10. Manuel RP, Marta GM, Douglas T, Brian RD, Emmanuel T, Kurinchi SG. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev. 2017; Mar 31;3(3):CD011639. doi: 10.1002/14651858.CD011639.pub2.
  • 11. Millis JM, Woodle ES, Piper JB, Bruce DS, Newell KA, Seaman DS, et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996; May 15;61(9):1365-9. doi: 10.1097/00007890-199605150-00014.
  • 12. Shang GP, Sun WL, Kyoung CD, Long J, Seong BH, Yu FZ. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation. 2014; Jul 15;98(1):22-8. doi: 10.1097/TP.0000000000000146.
  • 13. Akbulut S, Dogan Z, Baskiran A, Elbe H, Turkoz Y. Effect of a honey and arginine-glutamine-hydroxymethylbutyrate mixture on the healing of colon anastomosis in rats immunosuppressed with tacrolimus. Biotech Histochem. 2019; Oct;94(7):514-21. doi: 10.1080/10520295.2019.1601257
  • 14. Belgaied J-E. Resveratrol content of Tunisian wines. Journal of Wine Research. 2001; 12:47-52
  • 15. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother. 2002; Mar;56(2):84-7. doi: 10.1016/s0753-3322(01)00158-5.
  • 16. Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev. 2016; Jul;17(7):573-86. doi: 10.1111/obr.12409.
  • 17. Rodica PB, Andrew Y. Resveratrol and malignancies. Curr Pharmacol Rep. 2015; Aug;1(4):266-71. doi: 10.1007/s40495-015-0030-1
  • 18. Chibuike CU, Vanu RR, Rotimi EA, Peter JHJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008; Aug;66(8):445-54. doi: 10.1111/j.1753-4887.2008.00076.x.
  • 19. Sara H, Karen LT, Steen BP, Hendrik V, Jacob G, Henning G. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014; Apr 27;6(4):188-98. doi: 10.4254/wjh.v6.i4.188.
  • 20. Alessandra F, Mariangela DG, Vincenzo Z. Antioxidant dietary approach in treatment of fatty liver: new insights and updates. World J Gastroenterol. 2017; Jun 21;23(23):4146-57. doi: 10.3748/wjg.v23.i23.4146.
  • 21. Zakaria MMH, Hajipour B, Estakhri R, Saleh BM. Anti-oxidative effect of resveratrol on aluminum induced toxicity in rat cerebral tissue. Bratisl Lek Listy. 2017;118(5):269-72. doi: 10.4149/BLL_2017_053.
  • 22. Eva D, Alena P, Jolana C, Alejandro C, Lucie H, Milos H, et al. Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World J Gastroenterol. 2017; Nov 21;23(43):7678-92. doi: 10.3748/wjg.v23.i43.7678.

Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus

Year 2021, Volume 5, Issue 2, 144 - 148, 01.02.2021
https://doi.org/10.28982/josam.831592

Abstract

Background/Aim: Tacrolimus is a commonly used agent for immunosuppression in organ transplantation with known nephrotoxic effects. We think that kidney-sparing therapy should be added to current treatment protocols. We aimed to observe the protective effect of resveratrol (RSV) against the adverse effects of tacrolimus (TAC) on rat kidneys. Methods: Twenty-four rats were randomly divided into the following three groups of eight rats each: Control, TAC, and RSV. The control group was not treated in any way. Tacrolimus was administered to the TAC group. In addition to tacrolimus use, resveratrol was administered to the RSV group. At the end of the experiment, one kidney was used for histopathological examination and the other, for biochemical examination. Results were analyzed statistically. Results: IL-1β, IL-6, TNF-Alpha levels in the control group were significantly lower than those in TAC and RSV groups (IL-1; P<0.001, P<0.001, IL-6; P<0.001 P=0.002, TNF-Alpha; P<0.001, P<0.001), and those in the RSV group were significantly lower than those in the TAC group (IL-1: P=0.032, IL-6: P=0.001 TNF-Alpha: P=0.026). TAS levels of the control group were significantly higher than those of the TAC group (P=0.030). TOS and OSI levels of the control group were significantly lower than those of the TAC and RSV groups (TOS: P=0.002, P=0.012, OSI: P=0.001, P=0.004). In histopathological evaluation, the TAC group showed the highest levels of fibrosis. The differences between the control and TAC groups and the TAC and RSV groups were statistically significant (P=0.003, P=0.003). Conclusion: Resveratrol has a protective effect against the adverse effects of tacrolimus on the kidney, which may be because of its anti-inflammatory and antioxidant properties.

References

  • 1. Daniel A, Rainer O, Uwe H, Ondrej V, Licia P, Christophe M, et al. Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board. Nephrol Dial Transplant. 2018; Oct 1;33(10):1699-707. doi: 10.1093/ndt/gfx365.
  • 2. Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, et al. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level. Transpl Immunol. 2009; May;21(1):43-9. doi: 10.1016/j.trim.2009.02.002.
  • 3. Loong CC, Lin CY, Lui WY. Expression of interleukin-17 as a predictive parameter in acute renal allograft rejection. Transplant Proc. 2000; Nov;32(7):1773. doi: 10.1016/s0041-1345(00)01382-8.
  • 4. David IP. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005; May 15;10(10):688-91. doi: 10.1016/S1359-6446(05)03395-7.
  • 5. Meng Y, Mouze L, Wei Z, Yingzi M. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513-522. doi: 10.2174/1389200219666180129151948.
  • 6. Byung HC, Kyoung WK, Bo MK, Shang GP, Sun WL, Bum SC, et al. Dysregulation of Th17 cells during the early post-transplant period in patients under calcineurin inhibitor based immunosuppression. PLoS One. 2012;7(7):e42011. doi: 10.1371/journal.pone.0042011.
  • 7. Anne LW, Joseph AB, Ole V. mTOR: more targets of resveratrol?. Expert Rev Mol Med. 2013; Sep 23;15:e10. doi: 10.1017/erm.2013.11.
  • 8. Tomasz S, Katarzyna S. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 2015; Jun;1852(6):1145-54. doi: 10.1016/j.bbadis.2014.10.013.
  • 9. Lynn DC, R Neal S, Robert BC. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol. 2008;3:189-220. doi: 10.1146/annurev. pathmechdis.3.121806.151508.
  • 10. Manuel RP, Marta GM, Douglas T, Brian RD, Emmanuel T, Kurinchi SG. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev. 2017; Mar 31;3(3):CD011639. doi: 10.1002/14651858.CD011639.pub2.
  • 11. Millis JM, Woodle ES, Piper JB, Bruce DS, Newell KA, Seaman DS, et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996; May 15;61(9):1365-9. doi: 10.1097/00007890-199605150-00014.
  • 12. Shang GP, Sun WL, Kyoung CD, Long J, Seong BH, Yu FZ. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation. 2014; Jul 15;98(1):22-8. doi: 10.1097/TP.0000000000000146.
  • 13. Akbulut S, Dogan Z, Baskiran A, Elbe H, Turkoz Y. Effect of a honey and arginine-glutamine-hydroxymethylbutyrate mixture on the healing of colon anastomosis in rats immunosuppressed with tacrolimus. Biotech Histochem. 2019; Oct;94(7):514-21. doi: 10.1080/10520295.2019.1601257
  • 14. Belgaied J-E. Resveratrol content of Tunisian wines. Journal of Wine Research. 2001; 12:47-52
  • 15. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother. 2002; Mar;56(2):84-7. doi: 10.1016/s0753-3322(01)00158-5.
  • 16. Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev. 2016; Jul;17(7):573-86. doi: 10.1111/obr.12409.
  • 17. Rodica PB, Andrew Y. Resveratrol and malignancies. Curr Pharmacol Rep. 2015; Aug;1(4):266-71. doi: 10.1007/s40495-015-0030-1
  • 18. Chibuike CU, Vanu RR, Rotimi EA, Peter JHJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008; Aug;66(8):445-54. doi: 10.1111/j.1753-4887.2008.00076.x.
  • 19. Sara H, Karen LT, Steen BP, Hendrik V, Jacob G, Henning G. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014; Apr 27;6(4):188-98. doi: 10.4254/wjh.v6.i4.188.
  • 20. Alessandra F, Mariangela DG, Vincenzo Z. Antioxidant dietary approach in treatment of fatty liver: new insights and updates. World J Gastroenterol. 2017; Jun 21;23(23):4146-57. doi: 10.3748/wjg.v23.i23.4146.
  • 21. Zakaria MMH, Hajipour B, Estakhri R, Saleh BM. Anti-oxidative effect of resveratrol on aluminum induced toxicity in rat cerebral tissue. Bratisl Lek Listy. 2017;118(5):269-72. doi: 10.4149/BLL_2017_053.
  • 22. Eva D, Alena P, Jolana C, Alejandro C, Lucie H, Milos H, et al. Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. World J Gastroenterol. 2017; Nov 21;23(43):7678-92. doi: 10.3748/wjg.v23.i43.7678.

Details

Primary Language English
Subjects Surgery
Journal Section Research article
Authors

Hüseyin ÖZDEN> (Primary Author)
AHİ EVRAN ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0002-2786-3805
Türkiye


Muhammed GÖMEÇ>
CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0002-9127-3201
Türkiye


Yaşar ŞAHİN>
KIRIKKALE ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ
0000-0001-5936-4210
Türkiye


Gökhan KARACA>
KIRIKKALE YÜKSEK İHTİSAS HASTANESİ
0000-0002-5107-5999
Türkiye


Huri BULUT>
BEZM-İ ÂLEM VAKIF ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0003-2706-9625
Türkiye


Asuman KİLİTCİ>
ahi evran üniversitesi tıp fakültesi patoloji
0000-0002-5489-2222
Türkiye

Publication Date February 1, 2021
Published in Issue Year 2021, Volume 5, Issue 2

Cite

Bibtex @research article { josam831592, journal = {Journal of Surgery and Medicine}, eissn = {2602-2079}, address = {jsurgmed@gmail.com}, publisher = {Fatih BAŞAK}, year = {2021}, volume = {5}, number = {2}, pages = {144 - 148}, doi = {10.28982/josam.831592}, title = {Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus}, key = {cite}, author = {Özden, Hüseyin and Gömeç, Muhammed and Şahin, Yaşar and Karaca, Gökhan and Bulut, Huri and Kilitci, Asuman} }
APA Özden, H. , Gömeç, M. , Şahin, Y. , Karaca, G. , Bulut, H. & Kilitci, A. (2021). Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus . Journal of Surgery and Medicine , 5 (2) , 144-148 . DOI: 10.28982/josam.831592
MLA Özden, H. , Gömeç, M. , Şahin, Y. , Karaca, G. , Bulut, H. , Kilitci, A. "Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus" . Journal of Surgery and Medicine 5 (2021 ): 144-148 <https://dergipark.org.tr/en/pub/josam/issue/60239/831592>
Chicago Özden, H. , Gömeç, M. , Şahin, Y. , Karaca, G. , Bulut, H. , Kilitci, A. "Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus". Journal of Surgery and Medicine 5 (2021 ): 144-148
RIS TY - JOUR T1 - Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus AU - HüseyinÖzden, MuhammedGömeç, YaşarŞahin, GökhanKaraca, HuriBulut, AsumanKilitci Y1 - 2021 PY - 2021 N1 - doi: 10.28982/josam.831592 DO - 10.28982/josam.831592 T2 - Journal of Surgery and Medicine JF - Journal JO - JOR SP - 144 EP - 148 VL - 5 IS - 2 SN - -2602-2079 M3 - doi: 10.28982/josam.831592 UR - https://doi.org/10.28982/josam.831592 Y2 - 2021 ER -
EndNote %0 Journal of Surgery and Medicine Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus %A Hüseyin Özden , Muhammed Gömeç , Yaşar Şahin , Gökhan Karaca , Huri Bulut , Asuman Kilitci %T Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus %D 2021 %J Journal of Surgery and Medicine %P -2602-2079 %V 5 %N 2 %R doi: 10.28982/josam.831592 %U 10.28982/josam.831592
ISNAD Özden, Hüseyin , Gömeç, Muhammed , Şahin, Yaşar , Karaca, Gökhan , Bulut, Huri , Kilitci, Asuman . "Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus". Journal of Surgery and Medicine 5 / 2 (February 2021): 144-148 . https://doi.org/10.28982/josam.831592
AMA Özden H. , Gömeç M. , Şahin Y. , Karaca G. , Bulut H. , Kilitci A. Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus. J Surg Med. 2021; 5(2): 144-148.
Vancouver Özden H. , Gömeç M. , Şahin Y. , Karaca G. , Bulut H. , Kilitci A. Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus. Journal of Surgery and Medicine. 2021; 5(2): 144-148.
IEEE H. Özden , M. Gömeç , Y. Şahin , G. Karaca , H. Bulut and A. Kilitci , "Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus", Journal of Surgery and Medicine, vol. 5, no. 2, pp. 144-148, Feb. 2021, doi:10.28982/josam.831592